MUMBAI: Pharmaceutical firm Strides Arcolab on Thursday said it has received ANDA approvals for Famotidine Injection, used for treating stomach and intestinal ulcers.
The company has received ANDA approvals for Famotidine Injection in 10mg/ml - 2 ml, 4 ml and 20 ml concentration, Strides said in a filing to the Bombay Stock Exchange.
The product is licensed to Akorn-Strides LLC, a joint venture between the US company and Strides Arcolab.
"The Akorn-Strides partnership now has nine ANDA approvals for sterlite injectable products and
commercialisation is expected to commence shortly," Strides Arcolab Vice Chairman and group CEO Arun Kumar said.
Earlier in May 23, Strides Arcolab had received ANDA approval for Rifampicin Injection USP, 600 mg / vial.
Shares of the company were trading at Rs 149.60, down 0.60 per cent on the BSE in morning trade.
